Medicare Benefits Schedule - Item 73295

Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with advanced (FIGO III-IV) high-grade serous or high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible, requested by a specialist or consultant physician, to determine eligibility for olaparib under the Pharmaceutical Benefits Scheme (PBS)

Maximum of one test per patient’s lifetime

Fee: $1,200.00 Benefit: 75% = $900.00 85% = $1,112.10

(See para PN.0.27 of explanatory notes to this Category)

• Previous - Item 73294
• Next - Item 73296

Patients who are found to have any form of affected allele should be referred for post-test genetic counselling as there may be implications for other family members. Appropriate genetic counselling should be provided to the patient either by the specialist treating practitioner, a genetic counselling service or a clinical geneticist on referral.

Related Items: 73295 73296 73304 73333